Buddate Reges Intensive Treatment

Butylene Glycol, Hydrogenated Coconut Oil, Butyrospermum Parkii (shea) Butter, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7


Buddate Co Ltd
Human Otc Drug
NDC 71173-3000
Buddate Reges Intensive Treatment also known as Butylene Glycol, Hydrogenated Coconut Oil, Butyrospermum Parkii (shea) Butter, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7 is a human otc drug labeled by 'Buddate Co Ltd'. National Drug Code (NDC) number for Buddate Reges Intensive Treatment is 71173-3000. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Buddate Reges Intensive Treatment drug includes Butylene Glycol - 5.57 g/100mL Hydrogenated Coconut Oil - 4 g/100mL Palmitoyl Tetrapeptide-7 - .000006 g/100mL Palmitoyl Tripeptide-1 - .000006 g/100mL Shea Butter - 3 g/100mL . The currest status of Buddate Reges Intensive Treatment drug is Active.

Drug Information:

Drug NDC: 71173-3000
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Buddate Reges Intensive Treatment
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Butylene Glycol, Hydrogenated Coconut Oil, Butyrospermum Parkii (shea) Butter, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Buddate Co Ltd
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BUTYLENE GLYCOL - 5.57 g/100mL
HYDROGENATED COCONUT OIL - 4 g/100mL
PALMITOYL TETRAPEPTIDE-7 - .000006 g/100mL
PALMITOYL TRIPEPTIDE-1 - .000006 g/100mL
SHEA BUTTER - 3 g/100mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jan, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 06 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:BUDDATE Co Ltd
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:3XUS85K0RA
JY81OXM1OM
Q41S464P1R
RV743D216M
K49155WL9Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
71173-3000-170 mL in 1 TUBE (71173-3000-1)01 Jan, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Humectant & skin conditionnig (protectant)

Product Elements:

Buddate reges intensive treatment butylene glycol, hydrogenated coconut oil, butyrospermum parkii (shea) butter, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7 water palmitoyl tetrapeptide-7 palmitoyl tetrapeptide-7 shea butter shea butter palmitoyl tripeptide-1 palmitoyl tripeptide-1 butylene glycol butylene glycol hydrogenated coconut oil hydrogenated coconut oil

Indications and Usage:

Apply a generous amount of the cream three times a day to your body needing to be nourishd, and then softly massage your skin.

Warnings:

1. for external use only. 1) do not use over the wound and irritated skin with eczema or infections 2) discontinue using the product if signs of irritations and/or rashes occur and seek professional medical help 2. keep the cover closed tight after use 3. do not put the left over contents back into the container to avoid deterioration 1) avoid contact with eyes 2) keep out of reach of children 3) store in a cool and dry place, away from direct sun light

Dosage and Administration:

For external use only

Package Label Principal Display Panel:

1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.